Publications by authors named "Harold Yang"

Claim this Profile
A
A cross-sectional study of the role of epithelial cell injury in kidney transplant outcomes.
Philip F Halloran, Jessica Chang, Martina Mackova, Katelynn S Madill-Thomsen, Enver Akalin, Harold Yang

JCI Insight· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subthreshold rejection activity in many kidney transplants currently classified as having no rejection.
Philip F Halloran, Katelynn S Madill-Thomsen, Georg Böhmig, Jonathan Bromberg, Klemens Budde, Harold Yang

Am J Transplant· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SIM: The Surgery Imagery Mindset and Preparing for Surgery.
Michael J Asken, Vanessa A Hortian, Colby Elder, Harold C Yang

Am Surg· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor-free, Belatacept Plus Everolimus-based Immunosuppression.
V Ram Peddi, Bradley Marder, Luis Gaite, Jose Oberholzer, Ryan Goldberg, Harold Yang

Transplant Direct· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What do they know? What psychological skills in other professions can contribute to performance excellence in surgery.
Michael J Asken, Vanessa Hortian, Harold C Yang

Am J Surg· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prepping for surgery: Surgeon prepare thyself.
Michael J Asken, Harold C Yang, Renee Aboushi, Katsiaryna Paulovich

Am J Surg· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.
Flavio Vincenti, Goran Klintmalm, Harold Yang, V Ram Peddi, Paul Blahunka

Am J Transplant· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
Robert C Harland, Goran Klintmalm, Stephen Jensik, Harold Yang, Jonathan Bromberg

Am J Transplant· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.
Hélio Tedesco Silva, Harold C Yang, Herwig-Ulf Meier-Kriesche, Richard Croy, John Holman

Transplantation· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging.
Kenneth M Tichauer, Kimberley S Samkoe, Kristian J Sexton, Shannon K Hextrum, Harold H Yang

Mol Imaging Biol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protoporphyrin IX fluorescence contrast in invasive glioblastomas is linearly correlated with Gd enhanced magnetic resonance image contrast but has higher diagnostic accuracy.
Kimberley S Samkoe, Summer L Gibbs-Strauss, Harold H Yang, S Khan Hekmatyar, P Jack Hoopes

J Biomed Opt· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study.
Fuad S Shihab, Thomas H Waid, David J Conti, Harold Yang, Michael J Holman

Transplantation· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance.
Harold Yang

Am J Kidney Dis· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.
Robert Mendez, Thomas Gonwa, Harold C Yang, Samuel Weinstein, Stephen Jensik

Transplantation· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailoring tacrolimus-based immunotherapy in renal transplantation.
Harold C Yang

Nephrol Dial Transplant· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
Thomas Gonwa, Robert Mendez, Harold C Yang, Samuel Weinstein, Stephen Jensik

Transplantation· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation.
Nasimul Ahsan, Michael J Holman, Mark V Jarowenko, Mohammad S Razzaque, Harold C Yang

Am J Transplant· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis